We are pleased to announce the availability of the Early Embryo Viability Assessment Test (Eeva) to our patients undergoing an IVF cycle. RPMG was part of the study that led to FDA approval of the procedure.
Eeva is an FDA approved test using time-lapsed video to analyze early embryo development and aid in the selection of the best embryo for transfer, freezing or Preimplantation Genetic Screening or Diagnosis (PGS or PGD). At the heart of Eeva is software that was designed to assess critical differences in early embryo growth and determine an embryo’s viability and the potential for further development.
The Eeva Test was developed based on landmark research which discovered that early embryo growth events can predict embryo development and reflect the underlying health of the embryo.
Auxogyn Inc. recently completed a multi-center clinical trial, including RPMG, using Eeva with 54 patients and 758 embryos. The results from the trial supported that when embryologists used Eeva in conjunction with their traditional techniques they were able to predict with about 85% better probability than traditional morphology alone on day 3 which embryos will reach the blastocyst stage.
Eeva categorizes embryos as: High and Low. Embryologists can use this information along with traditional assessment based on morphology, to aid in identifying the best embryos as candidates for transfer, freezing or PGS/PGD: Eeva Result = High is more likely to continue to develop while Eeva Result = Low is less likely to continue to develop.
Eeva is now clinically available at Reproductive Partners to help you and your doctors make decisions about the chance that an embryo will develop to the blastocyst stage for transfer, freezing or PGS/PGD. Your doctor may recommend Eeva for your IVF cycle, or if you have any questions or concerns about Eeva, please ask your doctor. There is an additional cost for using Eeva in each IVF cycle.